Marshall Wace, LLP Moon Lake Immunotherapeutics Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Marshall Wace, LLP holds 1,154,385 shares of MLTX stock, worth $56.9 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,154,385
Previous 1,098,630
5.07%
Holding current value
$56.9 Million
Previous $48.3 Million
20.49%
% of portfolio
0.08%
Previous 0.07%
Shares
7 transactions
Others Institutions Holding MLTX
# of Institutions
124Shares Held
58.2MCall Options Held
52.2KPut Options Held
38K-
Bvf Inc San Francisco, CA21.8MShares$1.07 Billion34.86% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$418 Million30.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.98MShares$147 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$136 Million2.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.32MShares$114 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.82B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...